Pyrazole Compounds for Peripheral CB1 Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peripheral CB1 receptor antagonists, such as rimonabant, have adverse psychiatric side effects and there is a need for safe and efficacious drug candidates to treat disorders like obesity, non-alcoholic fatty liver disease, and type 2 diabetes without these side effects.
Innovation Solution
Development of pyrazole compounds that act as peripheral CB1 receptor antagonists, specifically designed to target peripheral tissues, reducing the risk of psychiatric side effects by minimizing central nervous system penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peripheral CB1 receptor antagonists are used to treat obesity and metabolic disorders, then therapeutic efficacy is improved, but psychiatric side effects occur due to central nervous system penetration
Solution Approach 1:
The patent applies local quality by designing compounds with selective tissue distribution properties. The pyrazole compounds are engineered to have high affinity for peripheral CB1 receptors while exhibiting low penetration into the central nervous system. This is achieved through specific molecular structure modifications that confer selective pharmacokinetic properties, allowing the drug to act locally in peripheral tissues (liver, adipose tissue) without affecting central nervous system receptors.
Solution Approach 2:
The patent employs the intermediary principle by using plasma proteins as a mediator to restrict drug distribution. The pyrazole compounds are designed to bind extensively to plasma proteins, which acts as a barrier preventing the drugs from crossing the blood-brain barrier. This protein binding intermediary allows the compounds to remain in the peripheral circulation where they can access peripheral CB1 receptors while being excluded from the central nervous system.
2Object-affected harmful factors
If central CB1 receptor antagonists are used, then psychiatric side effects are reduced, but therapeutic efficacy for peripheral disorders decreases
Solution Approach 1:
The patent achieves local quality by creating compounds with differential receptor accessibility. The pyrazole structure is designed to be accessible to peripheral CB1 receptors in tissues like liver and adipose tissue, while being inaccessible to central CB1 receptors due to pharmacokinetic restrictions. This spatial differentiation in drug-receptor interaction ensures therapeutic action at peripheral sites without central nervous system effects.
3Object-affected harmful factors
If drug penetration into central nervous system is minimized, then safety is improved, but ability to cross blood-brain barrier is reduced
Solution Approach 1:
The patent applies the extraction principle by selectively removing the blood-brain barrier crossing capability from the drug molecules. The pyrazole compounds are designed with molecular properties that prevent them from crossing the blood-brain barrier, effectively extracting this transport function. Meanwhile, the compounds retain full ability to interact with peripheral CB1 receptors, achieving selective peripheral action without central nervous system penetration.
Data Source
AI summary
Disclosed are pyrazole compounds, encompassed by formula (I) shown in the Specification, useful for treating peripheral cannabinoid 1 receptor mediated disorders. Also disclosed are pharmaceutical compositions and methods related to use of these compounds.